HIV

Individuals with HIV maintained similar rates of viral suppression after switching from a 3-drug regimen to the 2-drug regimen of dolutegravir plus lamivudine.

Top news of the day from across the health care landscape.

Prequalification tells global funders and Ministries of Health that the product meets global standards of quality, safety, and performance.

CDc11+ dendritic cells are the first to interact with HIV and transmit the virus to other cells in the body.

This funding is part of an effort to provide technical assistance to enhance efforts to end the HIV epidemic.

Fewer than 40% of people have ever had a HIV test, and less than 30% of people in the United States most at risk of acquiring HIV were tested in the past year.

In addition to offering on-site free and fast HIV testing, counselors from local agencies will answer questions about HIV prevention and treatment options, including PrEP, at certain Walgreens stores across the country.

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

In the statement, USPSTF officials noted that people who take PrEP should continue to use condoms and practice other behaviors to reduce their risk of other sexually transmitted infections.

Expanded mental health care at HIV clinics across the United States could help in reaching the goal of viral suppression among 90% of the population.

Many different strategies to achieve sustained virologic remission in HIV are being evaluated.

Case reports of sustained HIV-1 remission, new drug approvals, and resistance testing provide patients with potential novel therapy approaches.

Study could lead to advances in HIV vaccine development because functional immunity to HIV is needed from a vaccine.

Top news of the day from across the health care landscape.

Patients must be counseled about the risk of acute or chronic liver steatosis associated with all prescription and over the counter medications.

Effective treatment with ART has increased the life span of people living with HIV, but they remain at risk for chronic diseases.

Understanding what constitutes a 'good' immune response to HIV may provide important information for vaccine design and intervention.

This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.

On August 30, 2018, the FDA approved Merck’s doravirine (Pifeltro) a non-nucleoside reverse transcriptase inhibitor and doravirine/lamivudine/tenofovir (Delstrigo) a once-daily single tablet regimen for the treatment of HIV-1 infection in appropriate patients.

Kaposi sarcoma is a cancer caused by an associated herpesvirus that develops from the cells that line lymph or blood vessels, and most commonly affects individuals with HIV.

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status.

Results of the recent study, published in The Lancet, support the benefits of early testing and treatment for HIV, as well as the message of Prevention Access Campaign’s U=U (undetectable equals untransmittable) initiative.

"If successful, this has the potential to contribute to a cure for HIV."

Research investigates cytomegalovirus to understand the process of targeting HIV in order to eradicate it from the body.

Top news of the day from across the health care landscape.

In rare cases, patients with HIV can experience a paradoxical response to antiretroviral therapy known as extreme immune decline.

Study shows the importance of screening and treatment for depression, especially among patients with HIV since there has been an increase in life expectancy due to antiretroviral therapy.

Top news of the week from Specialty Pharmacy Times.

With this approval, patients who have never been treated have the option of a 2-drug regimen in a single tablet, as opposed to the standard-of-care 3-drug regimen for HIV.

With this approval, patients with HIV who have never been treated have the option of a 2-drug regimen in a single tablet.